Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells.
Salasznyk RM, Williams WA, Boskey A, Batorsky A, Plopper GE. · 2004
Read Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells. by Salasznyk RM, Williams WA, Boskey A, Batorsky A, Plopper GE. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc545655.txt.
Introduction
Salasznyk and co-authors test whether matrix contact alone can steer human stem cells toward bone. Their study appeared in the Journal of Biomedicine and Biotechnology. Mesenchymal stem cells live in bone marrow. They can become bone, cartilage, or fat. Chemical supplements usually drive that choice. The team suspected solid cues matter too. They plated cells on purified matrix proteins. Each protein is found in marrow. Cultures ran with or without soluble supplements.
Adhesion strength varied by protein. Fibronectin bound cells most tightly. Laminin-1 bound them least. Differentiation told a different story. Vitronectin and collagen I promoted bone fate best. Cells there made mineralized matrix over 16 days. Osteopontin, osteocalcin, and alkaline phosphatase appeared. Fibronectin plates showed almost no differentiation. Bare plates matched that failure. Matrix contact alone sufficed to induce the program.
Catalog record
| CREATOR | Salasznyk RM, Williams WA, Boskey A, Batorsky A, Plopper GE. |
|---|---|
| YEAR | 2004 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells By Roman M. Salasznyk, William A. Williams, Adele Boskey, Anna Batorsky, George E. Plopper Published in: Journal of Biomedicine and Biotechnology DOI: 10.1155/S1110724304306017 ABSTRACT The mechanisms controlling human mesenchymal stem cells (hMSC) differentiation are not entirely understood. We hypothesized that the contact with extracellular matrix (ECM) proteins normally found in bone marrow would promote osteogenic differentiation of hMSC in vitro. To test this hypothesis, we cultured hMSC on purified ECM proteins in the presence or absence of soluble osteogenic supplements, and assayed for the presence of well-established differentiation markers (production of mineralized matrix, osteopontin, osteocalcin, collagen I, and alkaline phosphatase expression) over a 16-day time course. We found that hMSC adhere to ECM proteins with varying affinity (fibronectin>collagen I≥collagen IV≥vitronectin>laminin-1) and through distinct integrin receptors. Importantly, the greatest osteogenic differentiation occurred in cells plated on vitronectin and collagen I and almost no differentiation took place on fibronectin or uncoated plates. We conclude that the contact with vitronectin and collagen I promotes the osteogenic differentiation of hMSC, and that ECM contact alone may be sufficient to induce differentiation in these cells. INTRODUCTION Human mesenchymal stem cells (hMSC) are a population of multipotent cells located within the bone marrow and are characterized by their ability to differentiate into at least three phenotypes when cultured in vitro [1, 2]. These cells are related to, but distinct from, stromal stem cells, and are carefully selected for uniform expression of approximately 50 surface antigens (with 98% homogeneity at passage 2), including at least three different stem cell surface marker proteins [1, 2]. Once isolated and purified from the marrow stroma, uncommitted hMSC retain the capacity to self-renew and differentiate along multiple pathways resulting in the generation and maintenance of an assortment of tissues. This in turn raises the possibility of utilizing these cells to repair or replace damaged tissues. A more complete understanding of the molecular mechanisms driving the differentiation of these cells should significantly facilitate the adoption of these cells in clinical applications. What drives the differentiation of hMSC is not entirely known. The development of these mesenchymal progenitors along an osteogenic [3], chondrogenic [4], and adipogenic [1] linage occurs primarily under the influence of chemical stimuli (eg, dexamethazone, transforming growth factor β3, insulin), which is accompanied by profound changes in morphology, proliferation, gene expression, and molecular signaling events. However, the underlying mechanisms governing mesenchymal stem cell differentiation in vitro and in vivo are not yet completely understood. Cellular differentiation is induced by cues in the environment immediately surrounding cells. Many of the soluble cues known to influence hMSC differentiation have been identified. For example, when hMSC are cultured in the presence of ascorbic acid-2-phosphate (AsAP), β-glycerophosphate (βGP), and the synthetic glucocorticoid dexamethasone (Dex), they adopt an osteoblastic phenotype and secrete and organize an extracellular matrix (ECM) where calcium phosphate is deposited as hydroxyapatite crystals [5]. Induction by this osteogenic supplement (OS) medium triggers a series of molecular events including activation of signal transduction pathways and expression of osteogenic marker genes including collagen I (COL I), osteocalcin, osteopontin, and alkaline phosphatase [1, 6, 7, 8]. While these media supplements clearly induce osteoblast differentiation under some conditions, they may suppress bone growth in vivo [9, 10], which may limit their usefulness for repairing bone in situ. Response to these agents is biphasic, concentration-dependent, and varies with the length of exposure [6, 11]. The result is a somewhat heterogeneous population of cells with mixed differentiation potential [12]. There is a clear need to better understand the molecular mechanisms that control osteogenesis in these cells. Insoluble cues that affect cellular differentiation arise largely from cellular binding to ECM proteins. While considerable attention has been paid to the role of OS medium in hMSC differentiation, comparatively little is known about the effect of ECM binding hMSC behavior. However, it is well known that ECM proteins play a major role in bone development. For example, during endochondral bone development, collagen II expression peaks during the chondrogenesis period while COL I deposition is maximal during the ossification phase [13]. Furthermore, it has been known for decades that single-point mutations in COL I yield a lethal form of osteogenesis imperfecta (eg, Pace et al [14]). In other studies, genetic knockouts of collagen II in mice result in severe developmental abnormalities and skeletal defects, especially in cartilaginous elements [15]. In vitro, bone marrow stromal cells undergo osteogenic differentiation when cultured on COL I matrix, and this requires interaction with the COL-I-binding integrin α2β1 [16, 17]. The mechanisms linking ECM binding to osteogenic differentiation, especially in hMSC, are largely unknown. ECM proteins typically affect cell behavior by binding to specific integrin cell surface receptors, which activate intracellular signaling pathways and control gene expression, cytoskeletal organization, and cell morphology. Over 20 different integrin receptors have been identified, which bind to well over 20 different ECM proteins and stimulate at least six different classes of intracellular signaling molecules: protein tyrosine kinases, serine/threonine kinases, lipid kinases, lipid phosphatases, protein phosphatases, and intracellular ion fluxes [18]. The contribution of integrin-associated pathways to osteogenic differentiation of hMSC is largely unknown. Recent evidence implicates ERK 1/2, an integrin- and growth factor-associated signaling protein, as playing a critical role in osteogenic differentiation of hMSC in vitro [1]. The role of ECM proteins in controlling ERK 1/2 activity and other signaling molecules during osteogenesis has not been investigated. How hMSC translate adhesion to ECM into cell differentiation is entirely unknown. We hypothesized that adhesion to ECM proteins, in the absence of soluble osteogenic stimulants, would enhance the osteogenic differentiation of hMSC. To test this hypothesis, we cultured hMSC on purified ECM proteins for 16 days in the presence or absence of soluble osteogenic supplements and assessed the differentiation of these cells by a variety of markers. Our results demonstrate that contact with COL I or vitronectin alone may be sufficient to induce differentiation in these cells. MATERIALS AND METHODS Materials Purified bovine COL I, human plasma vitronectin, and human plasma fibronectin proteins were purchased from Chemicon International (Temecula, Calif). Purified mouse collagen IV (COL IV) and mouse laminin-1 proteins were purchased from Collaborative Research Inc (Bedford, Mass). The α1-6 and β1-4 integrin function-blocking antibodies (Alpha integrin blocking and IHC kit, catalog # ECM 430; Beta integrin screening kit, catalog # ECM 440) and anti-human, rabbit IgG antibodies against osteopontin (catalog # AB1870) were obtained from Chemicon International (Temecula, Calif). Anti-human, mouse IgG antibody against tubulin was obtained from Sigma (St Louis, Mo) (catalog # T5168). Phalloidin conjugated to rhodamine (TRITC) was purchased from Molecular Probes (Eugene, Ore). Reverse transcriptase-polymerase chain reaction RT-PCR primers listed in Table 1 were purchased from IDT Technologies (Coralville, Iawa). [Table: Primers used for RT-PCR.] [Table: Osteogenic differentiation of hMSC plated on indicated substrates for 16 days, as assessed by indicated measurements of mineral to matrix ratio. By comparison, fully differentiated osteoblasts cultured on tissue culture plastic for 21 days have a ratio of approximately 5.4.] [Table: Values of total calcium in each well for all samples at day 16. The values were determined using a colorimetric assay.] Culture of hMSC and human osteoblasts Cryopreserved hMSC were purchased from Cambrex Inc (Walkersville, Md)